Page 2 - Muckle Wells Syndrome News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution

– ARCALYST® Q3 2023 net product revenue of $64.8 million, representing ~94% year-over-year growth – – KPL-404 Phase 2 rheumatoid arthritis data from Cohorts 1-3 now expected in Q1.

Rachel frankSanjk patelGlobenewswire incKiniksa pharmaceuticals ltdDrug administrationRegeneron pharmaceuticals incExchange commissionEuropean commissionChief executive officerRegeneron pharmaceuticalsFamilial cold autoinflammatory syndromeMuckle wells syndromeBreakthrough therapyOrphan drugOrphan drug designationPrivate securities litigation reform act

Anakinra by Swedish Orphan Biovitrum for Hospital Acquired Pneumonia (HAP): Likelihood of Approval

Anakinra is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Hospital Acquired Pneumonia (HAP).

United statesBiovitrum sobiAnakinra kineretGlobaldata pharmaceutical intelligence centerSwedish orphan biovitrumHospital acquired pneumoniaPhase transition success rate modelRheumatoid arthritisCryopyrin associated periodic syndromesNeonatal onset multisystem inflammatory diseaseChronic infantile neurologicalArticular syndromeMuckle wells syndromeFamilial cold autoinflammatory syndromeKawasaki diseaseStill disease

Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution

– ARCALYST® Q2 2023 net product revenue of $54.5 million –– ARCALYST 2023 net product revenue guidance increased to $220 - $230 million, representing ~84% year-over-year growth at the midpoint.

Rachel frankSanjk patelRoche groupEuropean commissionRegeneron pharmaceuticals incDrug administrationKiniksa pharmaceuticals ltdGlobenewswire incExchange commissionChief executive officerRegeneron pharmaceuticalsFamilial cold autoinflammatory syndromeMuckle wells syndromeBreakthrough therapyOrphan drugOrphan drug designation

Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Contactrachel frankSanjk patelEuropean commissionDrug administrationExchange commissionKiniksa pharmaceuticals ltdRegeneron pharmaceuticals incChief executive officerRegeneron pharmaceuticalsFamilial cold autoinflammatory syndromeMuckle wells syndromeBreakthrough therapyOrphan drugOrphan drug designationLooking statementsthisPrivate securities litigation reform act

Kiniksa Announces Results from Phase 3 Trial of Mavrilimumab in COVID-19-Related ARDS - Press Release

HAMILTON, Bermuda, Dec. 28, 2021 (GLOBE NEWSWIRE) Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) ("Kiniksa"), a biopharmaceutical company with a portf

Sanjk patelRachel frankExchange commissionKiniksa pharmaceuticals ltdDrug administrationKiniksa pharmaceuticalsChief executive officerOrphan drugFamilial cold autoinflammatory syndromeMuckle wells syndromeBreakthrough therapyPrivate securities litigation reform act